Secondary central nervous system lymphoma

International Journal of Hematology

Volumn 84, Issue 2, 2006, Pages 128-135

  Tomita, Naoto ^a   Kodama, Fumio ^b   Kanamori, Heiwa ^b   Motomura, Shigeki ^b   Ishigatsubo, Yoshiaki ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Central nervous system; Lymphoma; Prognosis; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; IDARUBICIN; IDARUBICINOL; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; HEADACHE; HISTOLOGY; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PAIN; PARESTHESIA; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; RISK FACTOR; SECOND CANCER; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA; STEM CELL TRANSPLANTATION; TUMOR LOCALIZATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; FEMALE; HUMANS; LYMPHOMA; MALE; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 33748416183     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06091     Document Type: Review

References (75)

1. Lister A. Secondary central nervous system lymphoma: the case for prophylaxis. Hematology (Am Soc Hematol Educ Program). 2002:290-293.
2. Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol. 1991;14: 478-482.
3. Tomita N, Kodama F, Sakai R, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma. 2000;38:335-343.
4. Bunn PA Jr, Schein PS, Banks PM, DeVita VT Jr. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood. 1976;47:3-10.
5. Law IP, Dick FR, Blom J, Bergevin PR. Involvement of the central nervous system in non-Hodgkin's lymphoma. Cancer. 1975;36: 225-231.
6. Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood. 1979;54:1249-1257.
7. Wolf MM, Olver IN, Ding JC, Cooper IA, Liew KH, Madigan JP. Non-Hodgkin's lymphoma involving the central nervous system. Aust N Z J Med. 1985;15:16-21.
8. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol. 1990;8:141-145.
9. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma: a multivariate analysis. Acta Oncol. 1996;35:703-708.
10. Herman TS, Hammond N, Jones SE, Butler JJ, Byrne GE Jr, McKelvey EM. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer. 1979;43:390-397.
11. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin's lymphomas. Cancer. 1980;45:545-552.
12. Lokich J, Galbo C. Leptomeningeal lymphoma: perspectives on management. Cancer Treat Rev. 1981;8:103-110.
13. Johnson GJ, Oken MM, Anderson JR, O'Connell MJ, Glick JH. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? Lancet. 1984;2: 685-687.
14. Murchison C. Case of 'lymphadenoma' of the lymphatic system, liver, lungs, heart and dura mater. Trans Pathol Soc Lond. 1870;21: 372-389.
15. Davison C, Michaels JJ. Lymphosarcoma with involvement of the central nervous system. Arch Intern Med. 1930;45:908-925.
16. Sparling HJ Jr, Adams RD, Parker F Jr. Involvement of the central nervous system by malignant lymphoma. Medicine. 1947;26: 285-332.
17. Williams HM, Diamond DH, Craver LF, Parsons H. Neurological Complications of Lymphomas and Leukemias. Springfield, Ill: Charles C. Thomas; 1959.
18. Young RC, Howser DM, Anderson T, Fisher RI, Jaffe E, DeVita VT Jr. Central nervous system complications of non-Hodgkin's lymphoma: the potential role for prophylactic therapy. Am J Med. 1979;66: 435-443.
19. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864-871.
20. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144-3150.
21. Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med. 1988;84:425-435.
22. Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 1999;32:571-576.
23. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etude des Lymphomes de l'Adulte. Ann Oncol. 2000;11: 685-690.
24. Jahnke K, Coupland SE, Na IK, et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood. 2005;106:384-385.
25. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496-502.
26. Griffin JW, Thompson RW, Mitchinson MJ, Kiewiet JC, Welland FH. Lymphomatous leptomeningitis. Am J Med. 1971;51:200-208.
27. MacKintosh FR, Colby TV, Podolsky WJ, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer. 1982;49:586-595.
28. Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91: 1178-1184.
29. Montoto S, Lister TA. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin North Am. 2005;19:751-763.
30. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004; 15:129-133.
31. Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2005;19:597-609.
32. DeAngelis LM, Cairncross JG. A better way to find tumor in CSF? Neurology. 2002;58:339-340.
33. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58:390-396.
34. Kersten MJ, Evers LM, Dellemijn PLI, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996;87:1985-1989.
35. Murase S, Saio M, Takenaka K, et al. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. Cancer Lett. 1998;132:181-186.
36. Gendelman S, Rizzo F, Mones RJ. Central nervous system complications of leukemic conversion of the lymphomas. Cancer. 1969;24: 676-682.
37. Aviles A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S. Primary breast lymphoma: results of a controlled clinical trial. Oncology. 2005;69:256-260.
38. Sapozink MD, Kaplan HS. Intracranial Hodgkin's disease: a report of 12 cases and review of the literature. Cancer. 1983;52:1301-1307.
39. Ersboll J, Schultz HB, Thomsen BLR, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985;35: 487-496.
40. Hoerni-Simon G, Suchaud JP, Eghbali H, Coindre JM, Hoerni B. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma: a study of 30 cases in a series of 498 patients. Oncology. 1987;44:98-101.
41. Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin lymphoma: a single-center study of 532 patients. Arch Neurol. 1997;54:854-859.
42. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099-1107.
43. Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol 2004;24:395-404.
44. Spectre G, Gural A, Amir G, Lossos A, Siegal T, Paltiel O. Central nervous system involvement in indolent lymphomas. Ann Oncol. 2005;16:450-454.
45. Laurenti L, Sica S, Voso MT, Chiusolo P, Zini G, Leone G. Central nervous system involvement after follicular large cell lymphoma. Haematologica. 2001;86:99.
46. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol. 1996;14:941-944.
47. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol. 1999;17:2479-2485.
48. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998;9:849-855.
49. Buckstein R, Lim W, Franssen E, Imrie KL. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma. 2003;44:955-962.
50. Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43:587-593.
51. Kawamura T, Koga S, Okamoto M, Kanno T, Iwamura H. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS). Radiat Med. 2001;19:145-149.
52. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer. 2002;95:576-580.
53. Batchelor T, Leahy N, Kaufman D. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma. Clin Lymphoma. 2001;2:116-119.
54. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16: 1561-1567.
55. Kasamon YL, Jones RJ, Piantadosi S, et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant. 2005;11:93-100.
56. Lotze C, Schuler F, Kruger WH, et al. Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study. Neuro-oncol. 2005;7:508-510.
57. Varadi G, Or R, Kapelushnik J, et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma. 1999; 34:185-190.
58. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome: a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol. 1994;12:2415-2422.
59. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466-468.
60. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica. 2004;89:753-754.
61. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116.
62. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol. 2005;131:13-21.
63. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005;131: 193-200.
64. Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia. 2002;16:1808-1817.
65. Moreton P, Morgan GJ, Gilson D, et al. The development of targeted chemotherapy for CNS lymphoma: a pilot study of the IDARAM regimen. Cancer Chemother Pharmacol. 2004;53:324-328.
66. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14:925-934.
67. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264-1274.
68. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
69. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol. 2000;27: 540-559.
70. Skarin AT, Canellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983;1:91-98.
71. Bos GM, van Putten WLJ, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol. 1998; 9:191-194.
72. Perez-Soler R, Smith TL, Cabanillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer. 1986;57: 971-977.
73. Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2002;43:1783-1788.
74. Tilly H, Lepage E, Coiffier B, et al, for the Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102: 4284-4289.
75. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, v.2.2006: Non-Hodgkin's Lymphoma. National Comprehensive Cancer Network Web site. Available at: http://www. nccn.org/professionals/ physician_gls/PDF/nhl.pdf. Accessed June 21, 2006.